JOHNSON & JOHNSON is 109.3x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($574.10 B vs $5.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APLS | JNJ |
|---|---|---|
| Market cap | $5.25 B | $574.10 B |
| US-listed rank | #1353 | #20 |
| Revenue (latest FY) | $1.00B | $94.19B |
| Net income (latest FY) | $22.39M | $26.80B |
| Net margin | 2.2% | 28.5% |
| P/E (trailing FY) | 234.6 | 21.4 |
| SEC filings | 1,217 | 984 |
JOHNSON & JOHNSON is 109.3x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($574.10 B vs $5.25 B).
In their latest fiscal years, Apellis Pharmaceuticals, Inc. reported $1.00B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Apellis Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.